Skip to content
value.today

Synlogic, Inc.: valuation

What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.

Cash-flow value

Free cash flow over the last three years averaged below zero, so a cash-flow value cannot be worked out.

Price to bookPrice to book of Biotechnology: $37 M to $146 M, median $54 M$0 M$39 M$79 M$118 M$158 M

Your own DCF model

A full discounted-cash-flow model of Synlogic, Inc., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.

Open the DCF model

Against the industry Biotechnology

Multiples of its companies with a market value at most 60 days old, times Synlogic, Inc.'s own figures of FY2025.

Values from the peers' multiples
MultiplePeers (25th / median / 75th)Synlogic, Inc.Applied toValue (25th to 75th)Companies
Price to book3.1× / 4.5× / 12.3×—book equity $12 M$37 M to $146 M70

Peers' multiples from the distributions by industry; the company's figures from its statements below. A multiple says what similar companies cost, not what this one is worth.

Against its own history

Synlogic, Inc.'s multiples at each month end with a market cap on file, Jan 2020 to May 2026, each against its own median.

Price to sales

4.9×

Now below its median of 30.3×, in the bottom quarter of its range; range 4.9× to 37.3× over 6 months.

0×9×19×28×37×20202021202220232024Price to sales 5×Median 30×

Price to book

0.7×

Now above its median of 0.6×; range 0.3× to 1.6× over 18 months.

0×0×1×1×2×2020202120222023202420252026Price to book 1×Median 1×

as of May 29, 2026. Market caps: the dated values on file since 2020, and in between the SEC's fails-to-deliver closing price times the share count on the latest 10-K or 10-Q cover. Each month divides by the last twelve months' results that had been published by then (a quarter 45 days after it ended, a fiscal year 60 days after), so the past is not read with figures that came out later; months with a loss give no P/E. Newest month: May 29, 2026.

The statements it starts from

USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.

Figures from the annual statements
Fiscal yearRevenueNet incomeCash from operationsCapital spendingFree cash flowNet debtSource
FY2025to Dec 31, 2025—$-1 M$-4 M$0 M$-4 M—SEC annual report (10-K, 20-F)
FY2024to Dec 31, 2024$0 M$-23 M$-32 M$0 M$-32 M—SEC annual report (10-K, 20-F)
FY2023to Dec 31, 2023$3 M$-61 M$-52 M$0 M$-52 M—SEC annual report (10-K, 20-F)
FY2022to Dec 31, 2022$1 M$-66 M$-57 M$1 M$-58 M—SEC annual report (10-K, 20-F)
FY2021to Dec 31, 2021$2 M$-61 M$-52 M$1 M$-53 M—SEC annual report (10-K, 20-F)
FY2020to Dec 31, 2020—$-59 M$-40 M$0 M$-40 M—SEC annual report (10-K, 20-F)

Each figure as filed; the full statements with every line and its filing are on the company page. Market value not on file.

How it is worked out: the cash-flow value is free cash flow grown at the first-stage rate for the years chosen, then at the long-run rate for ever, each year discounted at the risk-free rate plus the equity risk premium, less net debt. What the price assumes is the first-stage growth that makes that value equal today's market value. The starting cash flow, growth and net debt come from the statements; the risk-free rate from the US Treasury; the premium and the long-run growth are assumptions and are labelled so. This is arithmetic on reported figures, not advice.